Opinion

Video

Overview of the Port Delivery System with Ranibizumab

Margaret Chang, MD, examines the difficulties of frequent anti-VEGF injections and outlines the key aspects of the port delivery system (PDS) for ranibizumab administration.

  1. Why is sustained delivery of anti-VEGF necessary, and what challenges arise from frequent anti-VEGF injections?
  2. Can you provide an overview of the port delivery system with ranibizumab?
    1. How does the device function?
    2. How is the device implanted?
    3. How is the device refilled?
  3. What are the benefits of using the PDS with ranibizumab, and which patients are ideal candidates for this delivery method?
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) AGS 2025: Long-term efficacy and safety of standalone and phaco ELT with Marc Toeteberg-Harms, MD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
© 2025 MJH Life Sciences

All rights reserved.